Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2020 - 2024)

Aligos Therapeutics filings provide 5 years of Total Non-Current Liabilities readings, the most recent being $26.7 million for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 16.17% to $26.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $26.7 million, a 16.17% decrease, with the full-year FY2024 number at $26.7 million, down 16.17% from a year prior.
  • Total Non-Current Liabilities hit $26.7 million in Q4 2024 for Aligos Therapeutics, roughly flat from $26.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $57.4 million in Q1 2022 to a low of $26.1 million in Q1 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $41.9 million (2022), compared with a mean of $39.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 47.11% in 2022 and later fell 16.17% in 2024.
  • Aligos Therapeutics' Total Non-Current Liabilities stood at $45.3 million in 2020, then grew by 11.58% to $50.5 million in 2021, then dropped by 16.99% to $41.9 million in 2022, then decreased by 24.02% to $31.9 million in 2023, then fell by 16.17% to $26.7 million in 2024.
  • The last three reported values for Total Non-Current Liabilities were $26.7 million (Q4 2024), $26.7 million (Q3 2024), and $30.1 million (Q2 2024) per Business Quant data.